Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-α antagonists

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

(2008) E Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy

(2008) E. Keystone et al.   ARTHRITIS AND RHEUMATISM

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial

(2008)   ARTHRITIS AND RHEUMATISM

Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept

(2008) J. C. Cole et al.   RHEUMATOLOGY

Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future

(2008) J. D. Isaacs   RHEUMATOLOGY

Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden

(2007) M K Soderlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

(2007) H K Genant et al.   ANNALS OF THE RHEUMATIC DISEASES